No Data
No Data
No Data
No Data
No Data
Halozyme to Report First Quarter 2024 Financial and Operating Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on...
PR NewswireApr 23 08:30 ET
Halozyme Therapeutics (HALO) Is an Incredible Growth Stock: 3 Reasons Why
Yahoo FinanceApr 18 12:45 ET
Halozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know
Yahoo FinanceApr 18 12:00 ET
Halozyme Therapeutics Insider Sold Shares Worth $768,390, According to a Recent SEC Filing
Michael J. LaBarre, SVP, CHIEF TECHNICAL OFFICER, around April 16, 2024, sold 20,000 shares in Halozyme Therapeutics (HALO) for $768,390. Following the Form 4 filing with the SEC, LaBarre has control
MT NewswiresApr 18 06:46 ET
Halozyme Therapeutics(HALO.US) Officer Sells US$768.39K in Common Stock
$Halozyme Therapeutics(HALO.US)$ Officer LaBarre Michael J. sold 20,000 shares of common stock on Apr 16, 17, 2024 at an average price of $38.42 for a total value of $768.39K.Source: Announcement What
moomoo NewsApr 17 20:03 ET
Form 144 | Halozyme Therapeutics(HALO.US) Officer Proposes to Sell 384.89K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 17, $Halozyme Therapeutics(HALO.US)$ Officer MICHAEL LABARRE intends to sell 10,000 shares of its common stock on Apr 17, with a total market value of approximately $384.89
moomoo NewsApr 17 16:06 ET
No Data
No Data